| abstract |
Disclosed are anti-cancer pharmaceutical compositions, comprising: at least one anti-cancer drug selected from the group consisting of gefitinib, erlotinib, and sorafenib; and 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione dihydrochloride or a hydrate thereof as active ingredients, wherein the active ingredients are adapted for administration simultaneously or separately at different times. Also disclosed is their use for treating lung and kidney cancer. |